Structure of an inhibitor complex of the proteinase from feline immunodeficiency virus

Nature Structural Biology

Volumn 2, Issue 6, 1995, Pages 480-488

  Wlodawer, Alexander ^a   Gustchina, Alla ^a   Reshetnikova, Ludmila ^a,b   Lubkowski, Jacek ^a   Zdanov, Alexander ^a   Hui, Kwan Y ^c   Angleton, Eddie L ^c   Farmerie, William G ^d   Goodenow, Maureen M ^e   Bhatt, Deepa ^d   Zhang, Li ^d   Dunn, Ben M ^d  

^a NATIONAL CANCER INSTITUTE   (United States)

^b ENGELHARDT INSTITUTE OF MOLECULAR BIOLOGY   (Russian Federation)

^c ELI LILLY AND COMPANY   (United States)

^d Department of Biochemistry and Molecular Biology ^*  (United States)

^e UNIVERSITY OF FLORIDA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LP 149; PROTEINASE; PROTEINASE INHIBITOR; RECOMBINANT ENZYME; UNCLASSIFIED DRUG;

ARTICLE; CRYSTALLOGRAPHY; ENZYME INHIBITION; ENZYME STRUCTURE; ESCHERICHIA COLI; FELINE IMMUNODEFICIENCY VIRUS; GENE EXPRESSION; NONHUMAN; PRIORITY JOURNAL;

AMINO ACID SEQUENCE; AMINO ACIDS; ASPARTIC ENDOPEPTIDASES; BINDING SITES; COMPARATIVE STUDY; ENDOPEPTIDASES; HIV PROTEASE; IMMUNODEFICIENCY VIRUS, FELINE; KINETICS; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; MOLECULAR STRUCTURE; OLIGOPEPTIDES; PEPTIDES; PROTEASE INHIBITORS; PROTEIN CONFORMATION; SEQUENCE ALIGNMENT; STATISTICS; SUBSTRATE SPECIFICITY; SUPPORT, U.S. GOV'T, P.H.S.; VIRAL PROTEINS; X-RAY DIFFRACTION;

EID: 0029061580     PISSN: 10728368     EISSN: None     Source Type: Journal    
DOI: 10.1038/nsb0695-480     Document Type: Article

References (34)

1. Temin, H.M, in The Retroviridae (ed. Levy, J.A.) 1-18 (Plenum Press, New York; 1992).
2. Fauci, A S. The human immunodeficiency virus: Infectivity and mechanisms of pathogenesis. Science 239, 617-622 (1988).
3. Jask6lski, M., Miller, M., Rao, J.K.M., Leis, J. and Wlodawer, A. Structure of the aspartic proteinase from Rous Sarcoma retrovirus refined at 2-A resolution. Biochem. 29, 5889-5898 (1990).
4. Wlodawer, A. et al. Conserved folding in retroviral proteinases: Crystal structure of a synthetic HIV-1 proteinase. Science 245, 616-621 (1989).
5. Miller, M. et al. Structure of complex of synthetic HIV-1 proteinase with a substrate-based inhibitor at 2.3 A resolution. Science 246,1149-1152 (1989).
6. Wlodawer, A. and Erickson, J.W. Structure-based inhibitors of HIV-1 proteinase. A. Rev. Biochem. 62, 543-585 (1993).
7. Appelt, K. Crystal structures of HIV-1 proteinase-inhibitor complexes. Persp. in drug Discov. Design 1, 23-48 (1993).
8. Mulichak, A.M. et al. The crystallographic structure of the proteinase from human immunodeficiency virus type 2 with two synthetic peptidic transition state analog inhibitors. J biol. Chem. 268, 13103-13109 (1993).
9. Tong, L., Pav, S., Pargellis, C., Do, F., Lamarre, D. and Anderson, P.C. Crystal structure of human immunodeficiency virus (HIV) type 2 proteinase in complex with a reduced amide inhibitor and comparison with HIV-1 proteinase structures. Proc. natn. Acad. Sci. U.S.A. 90, 8387-8391 (1993).
10. Zhao, B., Winborne, E., Minnich, M.D., Culp, J.S., Debouck, C. and Abdel-Meguid, S.S. Three-dimensional structure of a simian immunodeficiency virus proteinase/inhibitor complex. Implications for the design of human immunodeficiency virus type 1 and 2 proteinase inhibitors. Biochemistry 32, 13054-13060 (1993).
11. Wilderspin, A.F. and Sugrue, R.J. Alternative native flap conformation revealed by 2.3 A resolution structure of SIV proteinase. J molec. Biol. 239, 97-103 (1994).
12. Pedersen, N.C. in: The Retroviridae (ed. Levy, J.A.) 181-228 (Plenum Press, New York; 1993).
13. Gardner, M.B. Simian and feline immunodeficiency viruses: animal lentivlrus models for evaluation of AIDS vaccines and antiviral agents. Antiviral Res. 15, 267-286 (1991).
14. Farmerie, W.G., Goodenow, M.M. and Dunn, B.M. Cloning, expression and kinetic characterization of the feline immunodeficiency virus proteinase. Adv. exp. med. Biol. 306, 511-513 (1991).
15. Elder, J.H. et al. Identification of proteolytic processing sites within the Gag and Pol polyproteins of feline immunodeficiency virus. J Virol. 67, 1869-1876 (1993).
16. Talbott, R.L. et al. Nucleotide sequence and genomic organization of feline immunodeficiency virus. Proc. natn. Acad. Sci. U S A. 86, 5743-5747 (1989).
17. Gustchina, A. in Aspartic Proteinases (ed. Takahashi, K.) (Plenum Publishing Corporation, New York; 1995).
18. Lin, Y. et al. Effect of point mutations on the kinetics and the inhibition of human immunodeficiency virus type 1 proteinase: Relationship to drug resistance. Biochemistry 34, 1143-1152 (1995).
19. Andreeva, N.S. in Structure and Biosynthesis of Proteins (ed. Makarova, R.F.) 97-114 (Scientific Center for Biological Publishing, Pushchino; 1988).
20. Harte, W.E. Jr., Swaminathan, S., Mansuri, M.M., Martin, J.C., Rosenberg, I.E. and Beveridge, D.L., Domain communication in the dynamical structure of human immunodeficiency virus proteinase. Proc. natn. Acad. Sci. U.S.A. 87, 8864-8868 (1990).
21. Gustchina, A. and Weber, I T. Comparative analysis of the sequences and structures of HIV-1 and HIV-2 proteases. Proteins 10, 325-339 (1991).
22. Sardana, V.V. et al. Human immunodeficiency virus type 1 protease inhibitors: Evaluation of resistance engendered by amino acid substitutions in the enzyme's substrate binding site. Biochemistry 33, 2004-2010 (1994).
23. Otto, MJ. et al. In vitro isolation and identification of human immunodeficiency virus (HIV) variants with reduced sensitivity to C-2 symmetrical inhibitors of HIV type 1 proteinase. Proc. natn. Acad. Sci. U.S.A. 90, 7543-7547 (1993).
24. Ho, D.D. et al. Characterization of human immunodeficiency virus type 1 variants with Increased resistance to a C2-symmetric proteinase inhibitor. J Virol. 68. 2016-2020 (1994).
25. Condra, J.H. et al. In vivo emergence of HIV-1 variants resistant to multiple proteinase inhibitors. Nature 374, 569-571 (1995).
26. Griffiths, J.T. et al. Different requirements for productive interaction between the active site of HIV-1 proteinase and substrates containing-hydrophobic*hydrophobic-or -aromatic*pro-cleavage sites. Biochemistry 31, 5193-5200 (1992).
27. Gellman, S.H. On the role of methionine residues in the sequence-independent recognition of nonpolar protein surfaces. Biochemistry 30, 6633-6636 (1991).
28. Thanki, N. et al. Crystal structure of a complex of HIV-1 protease with a dihydroxyethylene-containing inhibitor: comparisons with molecular modeling. Prot. Sci. 1, 1061-1072 (1992).
29. Hui, K.Y., Hermann, R.B., Manetta, J V., Gygi, T. and Angleton, E.L. Model peptides to study the effects of P2 and P3 substitutions in statine-containing HIV proteinase inhibitors. FEBS Lett. 327, 355-360 (1993).
30. Dunn, B.M., Scarborough, P.E., Davenport, R., and Swienicki, W. in: Methods in Molecular Biology (ed. Dunn, B.M. and Pennington, M.W.) 225-243 (Humana Press, Totowa; 1994).
31. Brunger, A. X-PLOR: A System for X-Ray Crystallography and NMR. (Yale University Press, New Haven; 1992).
32. Furey, W. and Swaminathan, S. Phases-A program package for the processing and analysis of diffraction data for macromolecules. Acta crystallogr. (1990).
33. Hendrickson, W.A. Stereochemically restrained refinement of macromolecular structures. Meth. Enzymol. 115, 252-270 (1985).
34. Finzel, B.C. Incorporation of fast Fourier transforms to speed restrained least-squares refinement of protein structures. J appl. Crystallogr. 20, 53-55 (1987).